Dianthus Therapeutics Inc [DNTH] stock is trading at $28.86, down -0.38%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The DNTH shares have gain 3.22% over the last week, with a monthly amount glided 15.81%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dianthus Therapeutics Inc [NASDAQ: DNTH] stock has seen the most recent analyst activity on July 26, 2024, when Robert W. Baird initiated its Outperform rating and assigned the stock a price target of $58. On May 16, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $40 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $44 on February 15, 2024. Jefferies initiated its recommendation with a Buy and recommended $22 as its price target on December 26, 2023. Wedbush started tracking with a Outperform rating for this stock on November 22, 2023, and assigned it a price target of $23. In a note dated October 30, 2023, Guggenheim initiated an Buy rating and provided a target price of $45 on this stock.
Dianthus Therapeutics Inc [DNTH] stock has fluctuated between $6.58 and $33.77 over the past year. Currently, Wall Street analysts expect the stock to reach $51 within the next 12 months. Dianthus Therapeutics Inc [NASDAQ: DNTH] shares were valued at $28.86 at the most recent close of the market. An investor can expect a potential return of 76.72% based on the average DNTH price forecast.
Analyzing the DNTH fundamentals
Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -23.07%, Pretax Profit Margin comes in at -18.78%, and Net Profit Margin reading is -18.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.21 and Total Capital is -0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.18 points at the first support level, and at 27.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.52, and for the 2nd resistance point, it is at 30.18.
Ratios To Look Out For
For context, Dianthus Therapeutics Inc’s Current Ratio is 42.52. Further, the Quick Ratio stands at 42.52, while the Cash Ratio is 36.8. Considering the valuation of this stock, the price to sales ratio is 376.46, the price to book ratio is 2.27.
Transactions by insiders
Recent insider trading involved Fairmount Funds Management LLC, Director, that happened on Sep 29 ’23 when 24670.0 shares were purchased. Director, Fairmount Funds Management LLC completed a deal on Sep 26 ’23 to buy 30000.0 shares. Meanwhile, Chief Medical Officer Randhawa Simrat bought 2000.0 shares on Sep 22 ’23.
